Highlights

Kenanga Research & Investment

Author: kiasutrader   |   Latest post: Fri, 27 Mar 2020, 9:21 AM

 

Pharmaniaga - Cloudy Mixture

Author:   |    Publish date:


FY19 core PATAMI of RM44.8m (+5% YoY) came in at 80% of our but at 112% of consensus forecasts. The variance from ours is due to lower-than-expected volume sales. However, we keep our FY20E earnings unchanged. The headline loss in 4QFY19 was due to PHARMA fulfilling its contractual obligations whereby the remaining unamortised costs in PHIS were amortised under the concession agreement. However, earnings visibility is cloudy beyond this interim period. TP is RM1.85. Reiterate UP.

FY19 core PATAMI of RM44.8m (-10% YoY) came in at 80% of our but at 112% of consensus forecasts. The variance from ours is due to lower-than-expected volume sales. No dividend was declared in this quarter which was unexpected bringing FY19 DPS to 6.0 sen.

Results’ highlights. QoQ, 4QFY19 top-line fell marginally by 0.2% due to flat overall demand from both concession and non-concession businesses in Malaysia and Indonesia. Nevertheless, the group registered a pre-tax loss of RM238m compared to a pre-tax profit of RM11.9m in 4QFY18 due to expensing a one-off RM247m revision in useful life of the rights to supply and provision of stock write off as a result of the voluntary Ranitidine product recall. However, headline Core PATAMI came in at RM15.4m (>+100% from low base in 3QFY19). The rights to supply are expenses incurred for Pharmacy Information System (PhIS) in providing and supplying to the Government certain hardware and software, being part and parcel of the contractual obligations under the concession agreement.

YoY, FY19 revenue rose 18% due to increased orders from concession and non-concession businesses and government hospitals. Nevertheless, FY19 register a headline loss of RM149m due to due to expensing a one-off RM247m revision in useful life of the rights to supply (concession) and provision of stock write off as a result of the voluntary Ranitidine product recall. However, core PATAMI rose 5% to RM44.8m thanks to better contribution from logistics and distribution.

Outlook. With the new contract arrangement as explained, the remaining unamortised rights to supply have been fully recognised. The Government has agreed to provide a 25-month interim period for procurement of drugs to Pharmaniaga Bhd after its concession ended on 30th Nov 2019. The interim period from 1st Dec 2019 to 31st Dec 2021 was to ensure no supply chain disruption in the supply and distribution of medicines nationwide while an open tender and appointment of a new concessionaire is developed. However, starting from 1st Dec 2019, the government will award Pharmaniaga a five-year contract extension for logistics and distribution of medicines based on its capabilities and performance. We highlight here that PBT margin for Logistics & Distribution segment is razor-thin, averaging at 0.8% over the past 13 quarters. We believe the contract extension for logistical support lies in Pharmaniaga’s capability in the development of a procurement and logistical computerised system i.e. Pharmacy Information System (PHIS). PHIS play a vital and integral role in ensuring the distribution of drugs to patients and effective management of stock levels.

Maintain UP. We maintain our FY19E/FY20E earnings. TP is RM1.85 based on 9x FY20E EPS which is -2.0SD below 5-year historical forward mean due to the cloudy earnings visibility beyond FY21. Reiterate Underperform.

Key risk is if it wins the open tender to retain the concession on satisfactory terms earlier than expected.

Source: Kenanga Research - 21 Feb 2020

Share this
Labels: PHARMA

Related Stocks

Chart Stock Name Last Change Volume 
PHARMA 1.21 0.00 (0.00%)

  Be the first to like this.
 


APPS
I3 Messenger
Individual or Group chat with anyone on I3investor
MQ Trader
Stock Screener using Technical and Fundamental criteria
MQ Affiliate
Join the MQ Affiliate Program today to earn rewards
 
 

2010 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 SCOMNET 0.470.00 
 KOTRA 1.890.00 
 UCREST 0.0550.00 
 EITA 1.050.00 
 PUC 0.080.00 
 WILLOW 0.370.00 
 IRIS 0.070.00 
 HSI-C9L 0.030.00 
 HOOVER 0.3950.00 
 BTECH 0.2050.00 

FEATURED POSTS

1. MQ Trader - Introduction to MQ Trader Affiliate Program MQ Trader Announcement!
2. MQ Affiliate – A smarter way to earn more rewards MQ Trader Affiliate Program
3. MQ Affiliate – How to become an effective affiliate MQ Trader Affiliate Program
4. MQ Affiliate – Upgrading to Affiliate Partner MQ Trader Affiliate Program

TOP ARTICLES

1. Why WHO chooses Malaysia to run trials on new drug to fight Covid-19? Koon Yew Yin Koon Yew Yin's Blog
2. Corona Virus to End May 29th; Economy slowdown to End Nov 2021, Says Indian Boy Who Correctly Predicted It's Start, 8 Months Ago Good Articles to Share
3. PM's speech on Prihatin Economic Stimulus Package (NFCP FIBERISATION IS ON!!) Calvin Tan Research THE INVESTMENT APPROACH OF CALVIN TAN
4. MYEG - UPGRADED TO OUTPERFORM BY CREDIT SUISSE (27 MARCH 2020) 东方不败
5. Covid-19 cases exceed 100,000 in the US - Koon Yew Yin Koon Yew Yin's Blog
6. This stock will do VERY well in the near term as the best is yet to come! Trend Trading 2030
7. 几乎一面倒唱衰股市的巨大声浪中,反抗直觉,想战胜人性,逆市操作,实实是一件不好受的苦差。 ABMB 银行为例,有很多股价已跌至十多年来最低,回顾1998,2009年谷底后猛回弹。
8. 【百股經#29】股市大跌!你不能錯過的10支好公司 - 百股經 Good Articles to Share
Partners & Brokers